Company Overview
PENTIXAPHARM HOLDING AG is a health‑care company listed on Xetra and trades in euros (EUR).
- Market Capitalisation: €46 340 000
- Recent Share Price: €1.80 (closing price 2026‑11‑10)
- 52‑Week High: €3.70 (2026‑02‑19)
- 52‑Week Low: €1.30 (2025‑11‑20)
Latest Financial Performance
On 12 November 2026, PENTIXAPHARM released its third‑quarter and nine‑month results for the fiscal year 2026, along with a confirmation of the revised annual outlook. The announcement was disseminated through multiple platforms, including EQS News, EQS‑Cockpit, and finanzen.net.
The statement, issued at 08:00 CET/CEST, contains the company’s own responsibility for the content. While the specific financial figures are not reproduced in the input, the release confirms that the company’s updated guidance remains unchanged.
Corporate Action – Convertible Bond Extension
Also on 12 November 2026, PENTIXAPHARM announced an extension of its convertible bond (Wandelanleihe) arrangement with Eckert & Ziegler SE. The bond’s call period (Abruffrist) and maturity have been extended to 2030, with accompanying adjustments to the bond’s terms. The disclosure was made in accordance with Article 17 of Regulation (EU) No 596/2014 and published via EQS News.
Regulatory Disclosure – § 50 WpHG Notification
On 11 November 2026, the company issued a notification under § 50 of the German Securities Trading Act (WpHG) to inform the European market about a regulatory change concerning derivative securities that confer a right to exchange or acquire shares. This communication, shared through EQS‑Cockpit and EQS News at 13:40 CET/CEST, fulfills the company’s obligation for the widespread dissemination of the regulatory update.
Summary
PENTIXAPHARM HOLDING AG has:
- Released its third‑quarter and nine‑month 2026 results, confirming the revised annual outlook.
- Extended its convertible bond with Eckert & Ziegler SE to 2030, adjusting terms accordingly.
- Published a § 50 WpHG notification regarding changes to derivative securities.
These developments provide a comprehensive update on the company’s financial performance, strategic bond management, and regulatory compliance for the reporting period.
